Deal Details

BELLUS Completes $79.4 Million Initial Public Offering

Healthcare

BELLUS initial public offering

Summary

BELLUS Health Inc. ("BELLUS Health” or the "Company”) (TSX: BLU and NASDAQ: BLU) recently completed an underwritten public offering of 11,179,451 shares of its common stock in Canada and the United States at a public offering price of $7.10 per share, which includes the partial exercise by the underwriters of their option to purchase an additional 1,320,296 shares of common stock. The gross proceeds to the Company from the offering, before deducting underwriting discounts and estimated offering expenses, are $79.4 million.

Baird served as lead manager on this offering

About

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company’s product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus. BELLUS Health is headquartered in Laval, Canada.

Healthcare

BELLUS initial public offering